Fingerprint
Dive into the research topics of 'Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of the Phase 2 CAPTIVATE Study'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically